FDA extends review of Capricor cell therapy; Pain drug startup to go public

The FDA has extended its review of Capricor Therapeutics' cell therapy deramiocel with a refined treatment indication, signaling regulatory delays but continued evaluation. Additionally, a pain drug startup co-founded by Vivek Ramaswamy is pursuing a rapid public listing, highlighting dynamic early-stage biotech capital movements.

This Wire brief sits within Fusion42's coverage of Biotech.